PMID: 6984778Jan 1, 1982Paper

Augmentin (amoxycillin and clavulanic acid) in the treatment of urinary tract infections

Scottish Medical Journal
A Leigh

Abstract

Augmentin (amoxycillin and clavulanic acid) is a new oral antibiotic combination which is particularly indicated in the treatment of urinary tract infections. Potentiation of amoxycillin by the clavulanic acid reduces the level of resistance in most Gram-negative urinary pathogens and these organisms are then sensitive to urinary levels of amoxycillin achieved on standard dosage. Clinical trials in urinary tract infections have shown a success rate of about 70 per cent for amoxycillin-resistant organisms. Augmentin in a dose of 375 mg tds is well tolerated and minimal gastrointestinal side effects occur. Augmentin is a novel antibiotic combination and will be particularly valuable in the oral treatment of urinary tract infections caused by multiply resistant bacteria.

References

Mar 1, 1978·Antimicrobial Agents and Chemotherapy·R WiseK A Bedford
Aug 1, 1978·Antimicrobial Agents and Chemotherapy·J W Paisley, J A Washington
Nov 1, 1978·Antimicrobial Agents and Chemotherapy·H C Neu, K P Fu
May 1, 1977·Antimicrobial Agents and Chemotherapy·C Reading, M Cole
Jan 1, 1982·The Journal of Antimicrobial Chemotherapy·D A Leigh

❮ Previous
Next ❯

Related Concepts

Related Feeds

Beta-lactamase Inhibitors

Beta-lactamase inhibitors are a class of antibiotics that inhibit beta-lactamases, a family of enzymes involved in bacterial resistance to beta-lactam antibiotics. Here is the latest research.

Beta-lactamase Inhibitors (ASM)

Beta-lactamase inhibitors are a class of antibiotics that inhibit beta-lactamases, a family of enzymes involved in bacterial resistance to beta-lactam antibiotics. Here is the latest research.